FIELD: biotechnology.
SUBSTANCE: antibodies to alpha-synuclein have been proposed. Also the following is proposed: DNA molecules encoding the said antibodies, mammalian cells transformed with DNA molecules and expressing antibodies, and a method of producing antibodies.
EFFECT: invention provides more effective blocking of the internalization of alpha-synuclein fibrils by antibodies to alpha-synuclein due to the ability of these antibodies to bind to both full-sized and fragmented aggregated alpha-synuclein molecules.
20 cl, 3 dwg, 7 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE IMMUNOGENS FROM C-TERMINAL END OF ALPHA-SYNUCLEIN PROTEIN AND COMPOSITIONS BASED ON THEM FOR TREATMENT OF SYNUCLEONOPATHIES | 2018 |
|
RU2810774C2 |
| HUMANIZED ANTIBODIES THAT RECOGNIZE ALPHA-SYNUCLEINE | 2012 |
|
RU2743738C2 |
| ANTIBODIES AGAINST ALPHA SYNUCLEIN | 2018 |
|
RU2787039C2 |
| MONOCLONAL ANTIBODIES TO ALPHA-SYNUCLEIN FOR PREVENTING TAU-PROTEIN AGGREGATION | 2017 |
|
RU2760334C2 |
| ANTIBODIES THAT BIND TO α-SYNUCLEIN PROTOFIBRILS | 2021 |
|
RU2810587C1 |
| AGENTS, APPLICATION WAYS AND METHODS FOR TREATING SYNUCLEOPATHY | 2016 |
|
RU2765303C2 |
| ANTIBODIES | 2018 |
|
RU2798399C2 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| THERAPEUTIC USE OF LONG-ACTING TRIPLE AGONIST CONJUGATE HAVING ACTIVITIES ON ALL GLUCAGON/GLP-1/GIP RECEPTORS FOR TREATING LUNG DISEASE | 2020 |
|
RU2829342C1 |
